163 related articles for article (PubMed ID: 37357017)
21. VPS33B negatively modulated by nicotine functions as a tumor suppressor in colorectal cancer.
Chen Y; Liu Z; Wang H; Tang Z; Liu Y; Liang Z; Deng X; Zhao M; Fu Q; Li L; Cai H; Xie W; Fang W
Int J Cancer; 2020 Jan; 146(2):496-509. PubMed ID: 31125123
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-7 Exerts Antiangiogenic Effect on Colorectal Cancer via ERK Signaling.
Fan X; Liu M; Tang H; Leng D; Hu S; Lu R; Wan W; Yuan S
J Surg Res; 2019 Aug; 240():48-59. PubMed ID: 30909065
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
[TBL] [Abstract][Full Text] [Related]
24. MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells.
Hondo N; Kitazawa M; Koyama M; Nakamura S; Tokumaru S; Miyazaki S; Kataoka M; Seharada K; Soejima Y
Cancer Lett; 2023 Jul; 567():216264. PubMed ID: 37336286
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death.
Augeri DJ; Langenfeld E; Castle M; Gilleran JA; Langenfeld J
Mol Cancer; 2016 Apr; 15():27. PubMed ID: 27048361
[TBL] [Abstract][Full Text] [Related]
26. Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer.
Xu X; Liu M; Peng K; Yu Y; Liu T
Clin Transl Oncol; 2023 Mar; 25(3):776-785. PubMed ID: 36609651
[TBL] [Abstract][Full Text] [Related]
27. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer.
Zhan T; Ambrosi G; Wandmacher AM; Rauscher B; Betge J; Rindtorff N; Häussler RS; Hinsenkamp I; Bamberg L; Hessling B; Müller-Decker K; Erdmann G; Burgermeister E; Ebert MP; Boutros M
Nat Commun; 2019 May; 10(1):2197. PubMed ID: 31097693
[TBL] [Abstract][Full Text] [Related]
28. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
[TBL] [Abstract][Full Text] [Related]
29. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
[TBL] [Abstract][Full Text] [Related]
30. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
31. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
32. Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death.
Jenkins LJ; Luk IY; Fairlie WD; Lee EF; Palmieri M; Schoffer KL; Tan T; Ng I; Vukelic N; Tran S; Tse JWT; Nightingale R; Alam Z; Chionh F; Iatropoulos G; Ernst M; Afshar-Sterle S; Desai J; Gibbs P; Sieber OM; Dhillon AS; Tebbutt NC; Mariadason JM
Mol Cancer Ther; 2023 Jan; 22(1):52-62. PubMed ID: 36343387
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN.
Chong X; Chen J; Zheng N; Zhou Z; Hai Y; Chen S; Zhang Y; Yu Q; Yu S; Chen Z; Bao W; Quan M; Chen ZS; Zhan Y; Gao Y
Mol Cancer; 2022 May; 21(1):118. PubMed ID: 35619132
[TBL] [Abstract][Full Text] [Related]
34. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
[TBL] [Abstract][Full Text] [Related]
35. Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.
Chang L; Shi R; Yang T; Li F; Li G; Guo Y; Lang B; Yang W; Zhuang Q; Xu H
J Exp Clin Cancer Res; 2013 Dec; 32(1):101. PubMed ID: 24314030
[TBL] [Abstract][Full Text] [Related]
36. MiR-3622a-3p acts as a tumor suppressor in colorectal cancer by reducing stemness features and EMT through targeting spalt-like transcription factor 4.
Chang S; Sun G; Zhang D; Li Q; Qian H
Cell Death Dis; 2020 Jul; 11(7):592. PubMed ID: 32719361
[TBL] [Abstract][Full Text] [Related]
37. DNMT3A facilitates colorectal cancer progression via regulating DAB2IP mediated MEK/ERK activation.
Zhou Y; Yang Z; Zhang H; Li H; Zhang M; Wang H; Zhang M; Qiu P; Zhang R; Liu J
Biochim Biophys Acta Mol Basis Dis; 2022 Apr; 1868(4):166353. PubMed ID: 35063646
[TBL] [Abstract][Full Text] [Related]
38. The sodium channel subunit SCNN1B suppresses colorectal cancer via suppression of active c-Raf and MAPK signaling cascade.
Qian Y; Zhou L; Luk STY; Xu J; Li W; Gou H; Chen H; Kang W; Yu J; Wong CC
Oncogene; 2023 Feb; 42(8):601-612. PubMed ID: 36564468
[TBL] [Abstract][Full Text] [Related]
39. Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids.
Elbadawy M; Hayashi K; Ayame H; Ishihara Y; Abugomaa A; Shibutani M; Hayashi SM; Hazama S; Takenouchi H; Nakajima M; Tsunedomi R; Suzuki N; Nagano H; Shinohara Y; Kaneda M; Yamawaki H; Usui T; Sasaki K
Biomed Pharmacother; 2021 Oct; 142():112043. PubMed ID: 34411919
[TBL] [Abstract][Full Text] [Related]
40. LRIG1 expression in colorectal cancer.
Ljuslinder I; Golovleva I; Palmqvist R; Oberg A; Stenling R; Jonsson Y; Hedman H; Henriksson R; Malmer B
Acta Oncol; 2007; 46(8):1118-22. PubMed ID: 17851870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
